Tag:
Seattle Genetics
Latest Headlines
Latest Headlines
Commentary: Biotech is a ripe field for insider-trading scandals
Bloomberg 's feature starts with the case of James Fan, the clinical programming manager at Seattle Genetics who contemplated suicide after being charged in a $200,000 insider trading case. Ultimately, Fan stepped back from the brink, but wound up in prison with an 18-month sentence and little in the way of career prospects.
Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact
With the armed antibody T-DM1 up for a groundbreaking approval soon, antibody-drug conjugates are hot. And Seattle Genetics, one of the leaders in the field, is riding the crest of that biotech wave with an expanded collaboration deal with Abbott Laboratories worth $25 million upfront and up to $220 million in milestones for each new cancer ADC they work on.
$27M funding will help advance Mersana's ADC pipeline
Mersana Therapeutics has raised $27 million in a Series A-1 financing led by new investor New Enterprise Associates (NEA), and will use the money to continue development of its Fleximer antibody-drug conjugate (ADC) platform and other ADCs. This is the first biopharma investment from NEA's recently announced $2.6 billion NEA 14 fund.
ASCO Highlights: Top stories from this year's meeting
Bristol-Myers presents promising PD-1 data; Genentech boasts solid T-DM1 results; GSK aces pivotal studies; Ariad's ponatinib shines; Bayer's regorafenib delays stomach cancer; Zytiga impresses in prostate cancer; Aveo makes a PhIII case for tivozanib; Seattle Genetics expands its CD-30 horizons; ADCs arrive.
ASCO Roundup: Key news from Bayer, Aveo, J&J and Seattle Genetics
Bayer looks to secure blockbuster status for regorafenib; J&J demonstrated impressive results among pre-chemo prostate cancer patients; Aveo raises the flag for tivozanib; Seattle Genetics plans to look at new indications for Adcetris.
Ventana to work with Seattle Genetics, Millennium on companion Dx
The companion diagnostic trend continues--and Ventana Medical Systems is involved yet again. This morning, Seattle Genetics and Takeda's Millennium unit announced that they are working with the Roche company on a companion diagnostic test for use in a study involving Adcetris.
Seattle Genetics to test Adcetris in non-Hodgkin's patients
Fresh off an approval for Hodgkin's lymphoma and another rare lymphoma, Seattle Genetics ( $SGEN ) is launching a new trial of its Adcetris treatment in non-Hodgkin's lymphoma. The Phase II trial will
Seattle Genetics prices Adcetris above $100K
Yet another $100,000-plus cancer treatment will soon hit the market. Seattle Genetics, which won early FDA approval for its new lymphoma drug Adcetris, has tagged it with a $13,500-per-dose price,
UPDATED: FDA pins approval on Seattle Genetics' cancer drug Adcetris
Seattle Genetics ( $SGEN ) has crossed the finish line. The FDA has granted the biotech an accelerated approval for Adcetris to treat Hodgkin's lymphoma and anaplastic large cell lymphoma. While it's
Seattle Genetics' stock falls despite panel recommendation
Seattle Genetics' stock price fell to $19.17 in pre-market trading despite yesterday's expert panel recommendation accelerated approval of the company's drug, brentuximab vedotin (Adcetris).
